Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin E Study Rules Out Cancer Prevention, Suggests Heart Risk Link

This article was originally published in The Tan Sheet

Executive Summary

Vitamin E manufacturers hoping for positive clinical news may have to wait for data from future trials, such as an NIH-sponsored prostate cancer prevention study, in the wake of another negative study published in the March 16 Journal of American Medical Association

You may also be interested in...



NIH suspends SELECT

The National Institutes of Health suspends research on whether vitamin E and selenium supplements prevent prostate cancer after prostate cases increased among the subjects taking only vitamin E and cases of adult onset diabetes increased in those taking selenium. The National Cancer Institute says Oct. 27 that data from the Selenium and Vitamin E Cancer Prevention Trial showed "small but not statistically significant" increases in the two conditions. NCI adds that "neither of these findings proves an increased risk from the supplements and both may be due to chance." The Southwest Oncology Group coordinated SELECT at more than 400 sites (1"The Tan Sheet" March 21, 2005, p. 13). More than 35,000 men aged 50 and older were randomly assigned to take selenium and vitamin E; selenium and a placebo; vitamin E and a placebo; or two placebos. NCI will advise SELECT participants to stop taking the supplements

NIH suspends SELECT

The National Institutes of Health suspends research on whether vitamin E and selenium supplements prevent prostate cancer after prostate cases increased among the subjects taking only vitamin E and cases of adult onset diabetes increased in those taking selenium. The National Cancer Institute says Oct. 27 that data from the Selenium and Vitamin E Cancer Prevention Trial showed "small but not statistically significant" increases in the two conditions. NCI adds that "neither of these findings proves an increased risk from the supplements and both may be due to chance." The Southwest Oncology Group coordinated SELECT at more than 400 sites (1"The Tan Sheet" March 21, 2005, p. 13). More than 35,000 men aged 50 and older were randomly assigned to take selenium and vitamin E; selenium and a placebo; vitamin E and a placebo; or two placebos. NCI will advise SELECT participants to stop taking the supplements

NIH suspends SELECT

The National Institutes of Health suspends research on whether vitamin E and selenium supplements prevent prostate cancer after prostate cases increased among the subjects taking only vitamin E and cases of adult onset diabetes increased in those taking selenium. The National Cancer Institute says Oct. 27 that data from the Selenium and Vitamin E Cancer Prevention Trial showed "small but not statistically significant" increases in the two conditions. NCI adds that "neither of these findings proves an increased risk from the supplements and both may be due to chance." The Southwest Oncology Group coordinated SELECT at more than 400 sites (1"The Tan Sheet" March 21, 2005, p. 13). More than 35,000 men aged 50 and older were randomly assigned to take selenium and vitamin E; selenium and a placebo; vitamin E and a placebo; or two placebos. NCI will advise SELECT participants to stop taking the supplements

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel